

Molecular insights of protein contours recognition with ligand pharmacophoric sites through combinatorial library design and MD simulation in validating HTLV PR inhibitors

Chandrabose Selvaraj<sup>1</sup>, Ankur Omer<sup>2</sup>, Poonam Singh<sup>\*2</sup> and Sanjeev Kumar Singh<sup>\*1</sup>

## Supplementary information

### Ligand Designing on R- Positions

From these contours are consider for requirement of additional elements in the known inhibitor and ligand rearrangement is done with use of Ligand designer script (Schrodinger) and ChemSketch, the ligand rearrangement position R1, R2, R3, R4 are marked by ligand designer script and attachment of atoms to known inhibitor position by ChemSketch, and ligand prepared through Ligprep.






Figure S1. (a), contours are analyzed for ligand rearrangement with pharmacophore rearrangement



**Figure S1 (b).** Represents the cartoon structure of contours with respective pharmacophore, and region of ligand requirement, and orange color spheres represents the ligand requirement and additional atoms attached at that R position.

## Derivatives of Ligand




**Figure S2.** The known inhibitor Purvalanol-A are added with the **Chain structure** - N - Propyl, N - Butyl, N - Pentyl, I - Propyl, I - Butyl, S - Butyl, T - Butyl, I - Amyl, **Cycle structure** – Cyclopropane, Cyclobutane, Cyclopentane, Cyclohexane, Cyclopentadiene, Benzene, Cycloheptane, Cyclooctane. **C-groups** – Vinyl, Allyl, Ethynyl, Cyano, Trifluoromethyl,

*Trichloromethyl, Triisopropylmethyl, Trityl, Benzyl, Benzoyl, Isobutiryl, Pivaloyl, Formyl, Acetyl, Carbomyl, Chloroformyl, Carboxyl, Methoxycarbonyl, Ethoxycarbonyl, Phenoxycarbonyl. Miscellaneous – Nitro, Isocyanato, Acetoxy, Sulfo, Phosphano, Nitroxy, Isothiocyanato, Acetoamido, Sulfino, Phosphito, Nitroso, Cyanato, Formyloxy, Sulfamoyl, Phosphato, Nitrosooxy, Thiocyanato, Formamido, Chlorosulfonyl, Methoxy, Azido, Isocyano, Sulfoamino, Sulfato, Trifyl. Protecting groups - T- Butyloxycarbonyl, Benzyloxycarbonyl, Dansyl, Tosyl, Trifluoroacetyl, Acetoacetyl, 9-Fluranylmethoxycarbonyl, Tetrohydropyranal in the R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> position of each inhibitor, and the new leads are obtained and are subjected to Site based molecular docking.*


### Active Site Prediction

Active site prediction of crystal structure of HTLV-PR, binding pocket present in between the two monomer chains, Z-Shaped binding pocket, which shows



**Figure S3.** (a) Represents the Site1 of the crystal structure of 2B7F, showing Z shaped binding pocket, colored in turquoise, present in between the two monomer chain (A and B chain), indicates both chains are to inhibited, by drug (active site binding pocket, resembles to HIV-PR)  
(b) The white colored dots indicates the Site1, represents the residues nearby the Site1 which having tendency to interact the ligand atoms, through hydrogen bond interaction.

**Figure S4**



**Figure S4:** Purvalanol A shows weak interactions with the mutant HTLV-1 PR.

### Molecular docking results in site based ligand docking

Site obtained from sitemap is used and site based ligand docking is performed, from that the libraries of Purvalanol-A is docked interacted through molecular docking. The top scores of the new leads, which are better than known Purvalanol-A(-6.702560) are given, for knowledge of predicted active site interaction.

Ligand Position	Addition of atoms	Docking score	H-Bonds	Active site
Purvalanol-A R1 Position	Fluroenylmethoxycarbonyl	-8.565992	2	GLY34, LEU57
	Danzyl	-8.366800	2	ARG10
	Carboxyl	-8.148589	2	ASP32, LEU57
	Phospho	-8.079790	2	GLY34, LEU57
	Phosphato	-8.077829	4	GLY34, ASP36, LEU57
	Acetoacetyl	-8.073759	2	ASP36, LEU57
	Cyclopentadiene	-7.982675	2	ASP36, LEU57
	Sulfoamino	-7.916354	4	ASP32, GLY34, ASP36, LEU57
	Nitroso	-7.852271	3	ASP32, GLY34
	Formyloxy	-7.690499	2	ASP36, LEU57
	Sulfamoyl	-7.678700	3	GLY34, ASP36, LEU57
	Phosphito	-7.455105	3	ASP36, LEU57
	Azido	-7.367854	2	GLY34, LEU57
	Tosyl	-7.314779	2	ASP36, LEU57
	Carbamoyl	-7.305788	2	LEU57, LEU30
	Phenyloxycarbonyl	-7.256961	3	ARG10, MET37
	Cyclopentane	-7.219739	2	GLY34, LEU57
	Vinyl	-7.065922	2	ASP36, LEU57
	Benzylloxycarbonyl	-7.029579	2	ARG10, MET37
	Sulfo	-6.999499	3	GLY34, ASP36, LEU57
	Trifluoromethyl	-6.990306	1	LEU57
	N-Pentyl	-6.987267	1	GLY34
	Iothiocyanato	-6.979956	2	GLY34, LEU57
	Trifluoroacetyl	-6.979547	1	GLY34
	Trichloromethyl	-6.951050	2	GLY34, ASP36
	Sulfato	-6.910771	2	ASP32, GLY34
	Benzyl	-6.892773	2	GLY34, LEU57
	Allyl	-6.866976	1	GLY34
	Isobutiryl	-6.852768	2	ASP36, LEU57

Table S1. Purvalanol-A attached library compounds at R1 position docking results with H-Bond interactions and active site involved in interaction are tabulated.

Purvalanol-A R2 Position				
Carboxyl	-9.093357	4	GLY34, ASP36, MET37	
Phosphato	-8.711677	4	ASP32, ASP36, LEU57	
Phosphito	-8.590773	3	ASP32, ASP36, LEU57	
Acetoacetyl	-8.399700	4	ASP32, ASP36, MET37, LEU57	
Cyclopentadiene	-8.179610	1	GLY34	
Benzoyl	-7.972852	1	LEU57	
Thiocyanato	-7.916242	2	GLY34, MET37	
Tosyl	-7.784949	3	ASP32, GLY34, MET37	
Benzyl	-7.701221	2	ASP32, LEU57	
Acetoxy	-7.696410	2	MET37, LEU57	
Trifluoroacetyl	-7.669722	2	MET37, LEU57	
T-butyl	-7.585948	1	GLY34	
Danzyl	-7.522937	4	GLY34, GLY58, ALA59	
Butyl	-7.489091	2	ASP32, LEU57	
Isobutyl	-7.459519	1	LEU57	
Fluroenylmethoxycarbonyl	-7.450053	3	ASP36, ALA59	
Formamido	-7.393833	2	GLY34, MET37	
Cyano	-7.350278	2	ASP32, LEU57	
Ethynyl	-7.350278	2	ASP32, LEU57	
Formyloxy	-7.343531	2	MET37, LEU57	
Benzyloxycarbonyl	-7.339480	4	GLY34, LEU57, ALA59	
Sulfoamino	-7.285997	1	MET37	
Chloroformyl	-7.269403	2	ASP32, LEU30	
N – Pentyl	-7.248576	1	GLY34	
Benzene	-7.248576	2	ASP32, GLY34	
Formyl	-7.177764	2	MET37, LEU57	
Acetamido	-7.138717	1	MET37	
Trifyl	-6.986313	3	ASP32, ASP36, LEU57	
Sulfato	-6.971282	2	ASP36, MET37	
Acetyl	-6.952335	2	ASP32, ASP36	
Cyanato	-6.945774	1	GLY34	
I-Amyl	-6.939794	2	GLY34, LEU57	
Pivaloyl	-6.931592	2	ASP32, GLY34	
Ethoxycarbonyl	-6.931443	2	ASP36, LEU57	
Tetrahydropyranal	-6.913617	1	GLY34	
Sulfamoyl	-6.913538	2	ASP32, LEU57	
Trityl	-6.837340	2	GLY34	
Phenoxy carbonyl	-6.809987	2	GLY34, ALA59	
Cyclobutane	-6.803285	1	ASP32	

Table S2. Purvalanol-A attached library compounds at R2 position docking results with H-Bond

interactions and active site involved in interaction are tabulated.

Purvalanol-A R3 Position				
Phenyloxycarbonyl	-10.208523	2	GLY34, MET37	
Phosphato	-10.028146	5	ASP32, GLY34, ASP36	
Chloroformyl	-9.967000	3	ASP32, GLY34, MET37	
Cycloheptane	-9.265767	1	ASP36	
Trifluoroacetyl	-9.141660	4	ASP32, GLY34, ASP36, MET37	
Phosphito	-9.085907	2	ASP36, LEU57	
Acetamido	-9.036692	2	ASP32, GLY34, ASP36, MET37	
Nitroxy	-8.934191	3	ASP32, GLY34, MET37	
Acetyl	-8.867921	3	ASP32, GLY34, ASP36	
Benzene	-8.831860	1	GLY34	
T – Butyl	-8.777912	2	ASP32, GLY34	
Trichloromethyl	-8.622579	2	ASP32, GLY34	
Sulfino	-8.548162	1	MET37	
Benzoyl	-8.519988	1	MET37	
Sulfato	-8.468488	2	GLY34, MET37	
Formamido	-8.308966	2	GLY34, MET37	
Benzyl	-8.303546	1	ASP36	
Formyl	-8.228145	3	ASP32, GLY34, MET37	
Chlorosulfonyl	-8.218263	3	ASP32, GLY34, ASP36	
Sulfoamino	-8.214180	4	ASP32, GLY34, LEU57	
T- Butyloxycarbonyl	-8.123968	1	GLY34	
Isobutiryl	-7.854320	2	ASP32, MET37	
Acetoacetyl	-7.813852	3	ASP32, GLY34, MET37	
Benzyloxycarbonyl	-7.777628	2	ASP32, MET37	
Thiocyanato	-7.722379	2	ASP32, GLY34	
Trifluoromethyl	-7.335328	2	ASP32, MET37	
Phosphano	-7.330417	4	GLY34, SER55, LEU57, GLN62	
Acetoxy	-7.312448	3	ASP32, GLY34, MET37	
S-Butyl	-7.277311	1	ASP32	
Cyclooctane	-7.258960	1	ASP36	
Formyloxy	-7.135790	2	ASP32, ASP36	
Cyano	-7.097047	2	ASP32, MET37	
Carboxyl	-7.035752	2	GLY34, MET37	
N – Propyl	-6.986083	1	GLY34	
Tosyl	-6.969499	2	ASP36, MET37	

Table S3. Purvalanol-A attached library compounds at R3 position docking results with H-Bond interactions and active site involved in interaction are tabulated.

Purvalanol-A R4 Position				
Formyl	-9.792020	4	ASP32, ASP36, LEU57	
Carboxyl	-9.295359	5	ASP32, ASP36, MET37, LEU57	
Fluroenylmethoxycarbonyl	-9.221705	4	ASP32, ASP36, ALA59	
Benzoyloxycarbonyl	-9.017948	4	ASP32, ASP36, ALA59	
Phenylloxycarbonyl	-8.812543	4	GLY34, LEU57, ALA59	
Phosphito	-8.773525	4	ASP36, MET37, LEU57	
Ethynyl	-8.645007	3	ASP32, GLY34, LEU57	
Acetoacetyl	-8.627168	2	ASP36, LEU57	
Phosphato	-8.520319	4	GLY34, ASN97, ALA99	
Trityl	-8.129960	5	ASP32, GLY34, LEU57	
Cycloheptane	-8.075769	2	ASP36, ALA59	
Propyl	-8.070831	3	ASP32, GLY34	
Cyano	-7.983771	3	ASP32, ASP36, LEU57	
Formyloxy	-7.838598	2	ASP32, MET37	
Phosphano	-7.792247	3	ASP32, GLY34, MET37	
Cyanato	-7.768998	3	ASP32, LEU57	
Danzyl	-7.686912	1	GLY34	
Acetoxy	-7.674101	3	ASP32, MET37	
Sulfino	-7.611824	3	ASP32, ASP36, LEU57	
Sulfato	-7.574927	2	ASN97, ALA99	
Thiocyanato	-7.434632	2	ASP32, LEU57	
Allyl	-7.430779	2	GLY34	
Cyclopropane	-7.304613	2	ASP32, GLY34	
Chloroformyl	-7.242689	2	GLY34, LEU57	
Cyclopentane	-7.212437	1	LEU57	
Vinyl	-7.148030	2	ASP32, GLY34	
Tosyl	-7.145920	2	ALA59	
T-Butyl	-7.077889	1	ALA59	
Benzyl	-6.989732	2	ASP36, ALA59	
T- Butyloxycarbonyl	-6.955697	3	ASP36, ALA59	
N – Pentyl	-6.953860	2	ALA59	

Table S4. Purvalanol-A attached library compounds at R4 position docking results with H-Bond interactions and active site involved in interaction are tabulated.